title: Lanzoprazole promotes gastric carcinogenesis in rats with duodenogastric reflux.
abstract: BACKGROUND
  Duodenogastric reflux is known to cause an increased frequency of cancer in the glandular portion of the stomach in rats. Furthermore, it is debated whether inhibition of gastric acid secretion may promote gastric carcinogenesis. In the present study we examined the combined effect of gastroduodenal reflux and acid inhibition with respect to the development of gastric carcinoma in the rat.
  
  
  METHODS
  Following the construction of a gastrojejunostomy in male Wistar rats, half of them were given the proton pump inhibitor lanzoprazole for 1 year. The rats were then killed and the pH in the stomach and gastrin in blood were measured. The stomach was examined macroscopically as well as histologically.
  
  
  RESULTS
  Gastrin levels at autopsy were significantly increased in treated rats compared to the control group, confirming an effect of lanzoprazole on gastric acid secretion. Body weight was significantly reduced in the treated rats. Thirty of 79 rats developed gastric cancer, and they were all adenocarcinomas of the Lauren intestinal type. Gastric cancers occurred significantly more often in lanzoprazole-treated rats (50%) compared with controls (27%).
  
  
  CONCLUSIONS
  Lanzoprazole given orally enhances the carcinogenic effect of duodenogastric reflux in rats.
authors.affiliation: Department of Surgery and The Gade Institute, Haukeland University Hospital, N-5021, Bergen, Norway.
authors.forename: Asgaut
authors.initials: A
authors.lastname: Viste
authors.forename: Kjell
authors.initials: K
authors.lastname: Øvrebø
authors.forename: Helga
authors.initials: H
authors.lastname: Maartmann-Moe
authors.forename: Helge
authors.initials: H
authors.lastname: Waldum
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000230:Adenocarcinoma / Q000209:etiology* / Q000503:physiopathology* / Q000662:veterinary; D000284:Administration, Oral; D000818:Animals; D004383:Duodenogastric Reflux / Q000150:complications* / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D005755:Gastrins / Q000032:analysis; D064747:Lansoprazole; D008297:Male; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*; D051381:Rats; D017208:Rats, Wistar; D013274:Stomach Neoplasms / Q000209:etiology* / Q000503:physiopathology* / Q000662:veterinary
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D004791:Enzyme Inhibitors; D005755:Gastrins; D064747:Lansoprazole; D009853:Omeprazole